Earnings summaries and quarterly performance for Crinetics Pharmaceuticals.
Executive leadership at Crinetics Pharmaceuticals.
R. Scott Struthers
Detailed
President and Chief Executive Officer
CEO
DP
Dana Pizzuti
Detailed
Chief Medical and Development Officer
IK
Isabel Kalofonos
Detailed
Chief Commercial Officer
JK
Jeff Knight
Detailed
Chief Operating Officer
SB
Stephen Betz
Detailed
Chief Scientific Officer
TS
Tobin Schilke
Detailed
Chief Financial Officer
Board of directors at Crinetics Pharmaceuticals.
Research analysts who have asked questions during Crinetics Pharmaceuticals earnings calls.
Catherine Novack
JonesTrading Institutional Services LLC
4 questions for CRNX
Also covers: ALDX, CAPR, DARE +3 more
Cory Jubinville
LifeSci Capital
4 questions for CRNX
Also covers: LQDA, TARS
Andy Chen
Wolfe Research, LLC
3 questions for CRNX
Also covers: ARGX, IMVT, INCY +7 more
Brian Skorney
Robert W. Baird & Co.
3 questions for CRNX
Also covers: ABUS, MIRM, MRNS +6 more
DL
David Lebowitz
Citigroup Inc.
3 questions for CRNX
Also covers: ALNY, ARWR, ASND +11 more
DT
Douglas Tsao
H.C. Wainwright & Co.
3 questions for CRNX
Also covers: ALKS, APLS, ARGX +19 more
JF
Jessica Fye
JPMorgan Chase & Co.
3 questions for CRNX
Also covers: ALKS, ALNY, AMRN +23 more
JS
Joseph Schwartz
Oppenheimer
3 questions for CRNX
Also covers: ASND, AUPH, BMRN +14 more
YR
Yasmeen Rahimi
Piper Sandler & Co.
3 questions for CRNX
Also covers: ALT, ARCT, CYTK +12 more
Gavin Clark-Gartner
Evercore ISI
2 questions for CRNX
Also covers: ACRS, ARGX, ASND +11 more
MS
Maxwell Skor
H.C. Wainwright & Co.
2 questions for CRNX
Also covers: ASND, AVIR, CYTK +4 more
Rohan Mathur
Oppenheimer & Co. Inc.
2 questions for CRNX
Also covers: CPRX, CYTK, VERU
Alexander Thompson
Stifel
1 question for CRNX
Also covers: ACRS, ARGX, ASND +4 more
Alex Thompson
Stifel Financial Corp.
1 question for CRNX
Also covers: ARGX, ASND, KYMR +1 more
AL
Anthea Li
Jefferies
1 question for CRNX
Also covers: ROIV, VERU
Catherine Okoukoni
Citizens JMP
1 question for CRNX
Also covers: ALT, KALV, MDGL +2 more
Charles Moore
Robert W. Baird & Co.
1 question for CRNX
Also covers: INKT
FD
Frances Dovell
TD Cowen
1 question for CRNX
Also covers: CELC, LNTH, TVTX
FD
Francis DiGiovanna
TD Securities
1 question for CRNX
GK
Gavin Kluck
Evercore ISI
1 question for CRNX
JF
Jessica Five
JPMorgan Chase & Co.
1 question for CRNX
Also covers: MRNA
JW
John Walden
Citizens JMP
1 question for CRNX
JW
John Wobel
Citizens JMP
1 question for CRNX
JS
Josh Schimmer
Cantor Fitzgerald
1 question for CRNX
Also covers: BBIO, BYSI, KRYS +3 more
KX
Katherine Xu
Citizens JMP
1 question for CRNX
LH
Lee Hung
Morgan Stanley
1 question for CRNX
Also covers: BLUE
LG
Leland Gershell
Oppenheimer & Co. Inc.
1 question for CRNX
Also covers: ARGX, ASND, CAPR +13 more
RL
Richard Law
Goldman Sachs
1 question for CRNX
Also covers: ARQT, MLYS
TV
Tyler Van Buren
TD Cowen
1 question for CRNX
Also covers: ADVM, ALLO, ARQT +12 more
Will Scheibler
Leerink Partners
1 question for CRNX
YR
Yasim Rahimi
Piper Sandler Companies
1 question for CRNX
YD
Yuchen Ding
H.C. Wainwright & Co.
1 question for CRNX
Also covers: ABUS, ARDX, RYTM
Recent press releases and 8-K filings for CRNX.
Crinetics Initiates Pediatric Phase 2/3 Trial for Atumelnant in CAH
CRNX
New Projects/Investments
- Crinetics Pharmaceuticals, Inc. has dosed the first patient in its BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant for the treatment of classic congenital adrenal hyperplasia (CAH) in children and adolescents.
- Atumelnant is a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist and is the first and only small molecule ACTH receptor antagonist in late-stage clinical development.
- The company recently received Orphan Drug Designation from the U.S. Food & Drug Administration for atumelnant in the treatment of classic CAH, and the BALANCE-CAH study is a potential registrational study.
Jan 22, 2026, 9:05 PM
Crinetics Pharmaceuticals, Inc. Provides Preliminary Q4 2025 Revenue and Business Update
CRNX
Earnings
Product Launch
New Projects/Investments
- Crinetics Pharmaceuticals, Inc. expects to report net product revenue from PALSONIFY (paltusotine) of over $5.0 million for the fourth quarter ended December 31, 2025. This estimate is preliminary and unaudited.
- As of January 8, 2026, the company reported approximately $1.4 billion in cash, cash equivalents, and investments.
- The company provided a business update at the J.P. Morgan Healthcare Conference, highlighting the early commercial success of PALSONIFY and the initiation of Phase 3 studies for Atumelnant in Congenital Adrenal Hyperplasia (CAH) and Carcinoid Syndrome (CS).
Jan 13, 2026, 10:02 PM
Crinetics Reports Strong Palsinify Launch and Pipeline Progress, Secured Funding Through 2030
CRNX
Product Launch
New Projects/Investments
- Crinetics Pharmaceuticals reported a successful launch of Palsinify for acromegaly, with over 200 patients enrolled and more than $5 million in revenue in 2025, and aims for it to become a blockbuster drug by expanding its prescriber base and activating patients.
- The company initiated Phase 3 studies for Paltusotine in carcinoid syndrome and Atumelnant in adult congenital adrenal hyperplasia (CAH), following positive Phase 2 data for Atumelnant showing dramatic reductions in biomarker A4.
- Crinetics is well-funded, with approximately $1.4 billion in the bank, providing a financial runway through 2030 and covering potential approvals for its pipeline products.
- A new compound, 9682, has entered Phase 1/2 studies for SST2-positive expressing solid tumors, expanding the company's pipeline.
Jan 13, 2026, 5:45 PM
Crinetics Pharmaceuticals reports strong 2025 performance and pipeline advancements
CRNX
Product Launch
New Projects/Investments
Guidance Update
- Crinetics Pharmaceuticals reported preliminary and unaudited ~$1.4 billion in cash, cash equivalents, and investments as of January 8, 2026, which is expected to fund operating plans well into 2030.
- The company launched PALSONIFY (paltusotine), achieving preliminary and unaudited >$5 million in net product revenue for 4Q2025.
- In 2025, Crinetics initiated Phase 3 studies for paltusotine in carcinoid syndrome (first patient randomized November 2025) and for atumelnant in adult congenital adrenal hyperplasia (CAH) (first patient randomized December 2025).
- A Phase 1/2 program for CRN09682 in neuroendocrine tumors (NETs) also commenced, with the first patient dosed in November 2025.
Jan 13, 2026, 5:45 PM
Crinetics Provides Business and Pipeline Updates at J.P. Morgan Healthcare Conference
CRNX
Product Launch
New Projects/Investments
Guidance Update
- Crinetics Pharmaceuticals reported Palsinify generated over $5 million in revenue in 2025, with more than 200 patients enrolled and over 125 unique prescribers in the last quarter.
- The company announced it is funded through 2030 with approximately $1.4 billion in the bank, which is expected to cover potential approvals for carcinoid syndrome, CAH, and atumelnant.
- Pipeline updates include the initiation of Phase 3 studies for paltusotine in carcinoid syndrome and atumelnant in adult CAH, as well as a Phase 1/2 study for 9682 in NETs.
- Crinetics aims to emerge as a premier endocrinology business by 2030, projecting two marketed products with four approved indications and seven additional clinical pipeline candidates.
Jan 13, 2026, 5:45 PM
Crinetics Reports 2025 Achievements, Strong Financial Position, and Pipeline Progress
CRNX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Crinetics reported a breakout year in 2025, highlighted by the FDA approval and successful launch of Palsinify for acromegaly, generating over $5 million in revenue and enrolling more than 200 patients.
- The company has secured funding through 2030, with approximately $1.4 billion in the bank, significantly de-risking future operations.
- Key pipeline advancements include positive Phase 2 data for atumelnant in CAH, initiation of Phase 3 studies for atumelnant and for Palsinify in carcinoid syndrome, and the start of Phase 1/2 studies for 9682 in neuroendocrine tumors.
- By 2030, Crinetics aims to become a premier endocrinology business with two marketed products and four approved indications, transitioning to be sustainably funded by revenue rather than solely equity capital.
Jan 13, 2026, 5:45 PM
Crinetics Pharmaceuticals Prices Public Offering of Common Stock
CRNX
New Projects/Investments
Product Launch
- Crinetics Pharmaceuticals announced the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price of $45.95 per share.
- The offering is expected to generate approximately $350 million in gross proceeds and is anticipated to close on or about January 8, 2026.
- The net proceeds will be used to fund commercial activities for the launch of PALSONIFY™, research and development of product candidates, other research programs, and general corporate purposes.
Jan 7, 2026, 2:22 AM
Crinetics Pharmaceuticals Announces Proposed Public Offering
CRNX
New Projects/Investments
- Crinetics Pharmaceuticals, Inc. intends to offer and sell $350.0 million of shares of its common stock in a proposed underwritten public offering.
- The company also plans to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of common stock.
- The net proceeds from the offering are intended to fund commercial activities for the launch of PALSONIFY™, research and development of product candidates, other research programs, and general corporate purposes.
- PALSONIFY™ is the first once-daily, oral treatment approved by the U.S. Food and Drug Administration (FDA) for adults with acromegaly.
Jan 5, 2026, 9:02 PM
Crinetics Pharmaceuticals Announces Strong PALSONIFY Launch and Positive Atumelnant Trial Results
CRNX
Earnings
Product Launch
New Projects/Investments
- Crinetics Pharmaceuticals, Inc. reported unaudited and preliminary net product revenue of over $5 million for PALSONIFY in the fourth quarter of 2025, following its FDA approval on September 25, 2025.
- The PALSONIFY launch demonstrated strong execution with over 200 enrollment forms received and over 125 unique prescribers by December 31, 2025.
- The company also announced positive topline results from the Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant, which achieved a 67% mean reduction in Androstenedione levels.
- Furthermore, 88% of participants in the atumelnant Phase 2 CAH study successfully reduced their glucocorticoid dose to physiologic replacement levels, with a favorable safety profile and no hepatic transaminase adverse events.
Jan 5, 2026, 9:01 PM
Crinetics Pharmaceuticals Provides Corporate Update on Palsonify Launch and Atumelnant Data
CRNX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Crinetics Pharmaceuticals announced $5 million in unaudited net Palsonify revenue for the fourth quarter, following its first full quarter after approval in late September.
- The Palsonify launch has processed over 200 enrollment forms and engaged more than 125 unique prescribers, with 50% of filled prescriptions rapidly reimbursed and the vast majority of prior authorizations lasting 12 months.
- The company reported positive top-line results from Cohort 4 of the Atumelnant Phase 2 CAH study, demonstrating a 67% reduction in A4 that was sustained despite reduced glucocorticoid doses.
- Crinetics is advancing Atumelnant into a Phase 3 Calm CAH study, designed to evaluate safety and efficacy in 150 patients, with a primary endpoint of achieving normal A4 levels on a physiologic glucocorticoid dose.
Jan 5, 2026, 1:30 PM
Quarterly earnings call transcripts for Crinetics Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more